X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nvp-bez235 (221) 221
humans (174) 174
index medicus (173) 173
oncology (144) 144
cell line, tumor (105) 105
tor serine-threonine kinases - antagonists & inhibitors (95) 95
imidazoles - pharmacology (86) 86
cancer (84) 84
quinolines - pharmacology (84) 84
animals (82) 82
phosphatidylinositol 3-kinases - antagonists & inhibitors (80) 80
apoptosis (76) 76
pi3k (76) 76
female (73) 73
mtor (72) 72
rapamycin inhibitor (68) 68
phosphatidylinositol 3-kinase/mammalian target (65) 65
signal transduction - drug effects (65) 65
tor serine-threonine kinases - metabolism (63) 63
cell proliferation - drug effects (61) 61
mice (61) 61
antineoplastic agents - pharmacology (59) 59
pathway (59) 59
growth (58) 58
phosphatidylinositol 3-kinases - metabolism (58) 58
mammalian target (51) 51
phosphorylation (49) 49
protein kinase inhibitors - pharmacology (48) 48
rapamycin (45) 45
cell biology (43) 43
apoptosis - drug effects (41) 41
dual pi3k/mtor inhibitor (41) 41
kinases (41) 41
akt (40) 40
proto-oncogene proteins c-akt - metabolism (40) 40
autophagy (37) 37
drug synergism (37) 37
mutation (37) 37
xenograft model antitumor assays (37) 37
activation (36) 36
breast cancer (36) 36
resistance (36) 36
mutations (35) 35
male (34) 34
signal transduction (33) 33
tumors (33) 33
chemotherapy (32) 32
cells (31) 31
antitumor-activity (30) 30
proteins (30) 30
inhibitor nvp-bez235 (29) 29
mice, nude (29) 29
biochemistry & molecular biology (26) 26
care and treatment (26) 26
expression (26) 26
analysis (25) 25
breast-cancer (25) 25
health aspects (25) 25
antineoplastic agents - therapeutic use (24) 24
article (24) 24
cancer therapies (24) 24
cancer-cells (24) 24
pharmacology & pharmacy (24) 24
phosphatidylinositol 3-kinase - antagonists & inhibitors (24) 24
research (24) 24
cell growth (23) 23
dose-response relationship, drug (23) 23
in-vivo (23) 23
imidazoles - therapeutic use (22) 22
therapy (22) 22
1-phosphatidylinositol 3-kinase (21) 21
cell proliferation (21) 21
cell survival - drug effects (21) 21
genetic aspects (21) 21
quinolines - therapeutic use (21) 21
tor protein (21) 21
breast neoplasms - drug therapy (20) 20
cell cycle (20) 20
protein kinase inhibitors - therapeutic use (20) 20
inhibitors (19) 19
antineoplastic combined chemotherapy protocols - pharmacology (18) 18
bez235 (18) 18
everolimus (18) 18
proto-oncogene proteins c-akt - antagonists & inhibitors (18) 18
research article (18) 18
sirolimus - pharmacology (18) 18
drug resistance (17) 17
morpholines - pharmacology (17) 17
pi3k/mtor inhibitor (17) 17
cancer research (16) 16
cell cycle - drug effects (16) 16
imidazoles - administration & dosage (16) 16
medicine (16) 16
middle aged (16) 16
phosphatidylinositol 3-kinase - metabolism (16) 16
phosphatidylinositol 3-kinases - genetics (16) 16
quinolines - administration & dosage (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
breast neoplasms - genetics (15) 15
colorectal cancer (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science Translational Medicine, ISSN 1946-6234, 07/2018, Volume 10, Issue 449, p. eaaq1564
Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune... 
RAPAMYCIN | TARGET | MEDICINE, RESEARCH & EXPERIMENTAL | DISEASE | GROWTH | NVP-BEZ235 | RESISTANCE | MTOR | CELL BIOLOGY
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 07/2019, Volume 62, Issue 13, pp. 6241 - 6261
The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is frequently overactivated in cancer, and drives cell growth,... 
NVP-BYL719 | CHEMISTRY, MEDICINAL | PQR309 | METABOLISM | 3-KINASE/MAMMALIAN TARGET | GROWTH | NVP-BEZ235 | IDENTIFICATION | PI3K/MTOR INHIBITOR | PHOSPHOINOSITIDE 3-KINASE | WORTMANNIN
Journal Article
Molecular cancer therapeutics, ISSN 1535-7163, 4/2015, Volume 14, Issue 4, pp. 1014 - 1023
PI3K/AKT/mTOR pathway which is aberrantly stimulated in many cancer cells, has emerged as a target for therapy. However, mTORC1/S6K also mediates negative... 
PKI-587 | RAF | NVP-BEZ235 | GDC-0980 | Rictor | AKT | PD0325901
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2018, Volume 61, Issue 3, pp. 881 - 904
On the basis of novel pyrazino[2,3-c]quinolin-2(1H)-one scaffold, we designed and identified a highly selective, potent and oral mTOR inhibitor, 9m. Compound... 
MAMMALIAN TARGET | RAPAMYCIN MTOR | CHEMISTRY, MEDICINAL | ONCOLOGY | 3-KINASE | PATHWAY | DUAL PI3K/MTOR INHIBITOR | BIOAVAILABLE INHIBITORS | NVP-BEZ235 | KINASE INHIBITOR | DISCOVERY | Index Medicus
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 07/2016, Volume 21, Issue 7, pp. 787 - 788d
作者总结 经验 • 本研究结果强调了PI3K/mTOR双重抑制在临床环境中的额外毒性, 而在临床前模型中并未预见到这种毒性。 • 鉴于当前配方BEZ235具有毒性又缺乏有效性, 不应在肾细胞癌患者中开展进一步研究。 摘要 背景 . 哺乳动物雷帕霉素靶蛋白复合物1 (mTORC1) 变构抑制剂获批用于治疗晚期肾细胞癌... 
ACTIVATION | THERAPY | EVEROLIMUS | EFFICACY | ONCOLOGY | PHOSPHORYLATION | PATHWAY | GROWTH | NVP-BEZ235 | TUMORS | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Imidazoles - adverse effects | Middle Aged | Male | Antineoplastic Agents - therapeutic use | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Female | Aged | Quinolines - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | Quinolines - adverse effects | Index Medicus | Clinical Trial Results
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 11/2018, Volume 19, Issue 11, pp. 1015 - 1022
The PI3K/mTOR pathway is one of the most frequently aberrantly activated pathways in human malignancies, such as renal cell carcinoma (RCC), and contributes to... 
antitumor growth | PI3K/mTOR inhibitor | renal cell carcinoma | SN202 | MAMMALIAN TARGET | RAPAMYCIN | ACTIVATION | PHOSPHATIDYLINOSITOL 3-KINASE | NVP-BEZ235 | TRASTUZUMAB RESISTANCE | MTOR | PI3K | ONCOLOGY | PATHWAY | GROWTH
Journal Article
INTERNATIONAL JOURNAL OF CANCER, ISSN 0020-7136, 07/2013, Volume 133, Issue 2, pp. 505 - 513
Acquired resistance to epidermal growth factor receptortyrosine kinase inhibitors (EGFRTKIs), such as gefitinib and erlotinib, is a critical problem in the... 
APOPTOSIS | HGF | ACQUIRED-RESISTANCE | NVP-BEZ235 | SENSITIVITY | INDUCTION | PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET | GEFITINIB RESISTANCE | EGFR mutation | PI3K | MET AMPLIFICATION | ONCOLOGY | PATHWAY | EGFR-TKI resistance | mTOR | MUTATIONS
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2014, Volume 20, Issue 5, pp. 1235 - 1248
Journal Article
Journal Article
Cell Cycle, ISSN 1538-4101, 12/2017, Volume 16, Issue 24, pp. 2386 - 2395
Cyclin D1 and cyclin E1, as vital regulatory factors of G1-S phase cell cycle progression, are frequently constitutive expressed and associated with... 
NVP-BEZ235 | neuroblastoma | GSK3β | cyclin D1 | cyclin E1 | APOPTOSIS | PROLIFERATION | LUNG-CANCER CELLS | OVARIAN-CANCER | CELL BIOLOGY | ANTICANCER ACTIVITY | DUAL PI3K/MTOR INHIBITOR | PROSTATE-CANCER | GROWTH | S-PHASE | GSK3 beta | PROGRESSION
Journal Article
19.